Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
A phase 1/2 trial of Saruparib, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer and prostate cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT04644068 by AstraZeneca, with 702 participants enrolled, started 2020-11-12 and due to reach its primary completion in 2027-05-28. Interventions recorded: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd. Conditions listed: Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin, Small-cell lung cancer.
- TrialStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Shares Datopotamab deruxtecan, AstraZeneca, Carboplatin, Ovarian cancer.
- TrialA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan
Shares Datopotamab deruxtecan, AstraZeneca, Carboplatin, Small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s
Shares Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin, Small-cell lung cancer.
- TrialVolrustomig Priming Regimens Exploratory Phase II Platform Study
Shares Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin, Small-cell lung cancer.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Trastuzumab deruxtecan, AstraZeneca, Carboplatin, Small-cell lung cancer.
- TrialSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Shares Saruparib, AstraZeneca, Prostate cancer.
- TrialA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Shares Saruparib, AstraZeneca, Prostate cancer.